Academic Journal
Striving toward hepatitis C elimination in the era of COVID-19.
| Τίτλος: | Striving toward hepatitis C elimination in the era of COVID-19. |
|---|---|
| Συγγραφείς: | Lanièce Delaunay C; Department of Epidemiology, Biostatistics, and Occupational Health, School of Population and Global Health, McGill University, Montreal, Quebec, Canada.; Department of Medicine, McGill University Health Centre, Montreal, Quebec, Canada., Greenwald ZR; Division of Epidemiology, Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada., Minoyan N; Centre de Recherche du Centre Hospitalier de l'Université de Montréal, Montreal, Quebec, Canada.; Département de Médecine Sociale et Préventive, École de Santé Publique, Université de Montréal, Montreal, Quebec, Canada., Artenie AA; Population Health Sciences, University of Bristol, Bristol, United Kingdom., Jeong D; School of Population and Public Health, University of British Columbia, Vancouver, British Columbia, Canada.; British Columbia Centre for Disease Control, Vancouver, British Columbia, Canada., Marathe G; Department of Epidemiology, Biostatistics, and Occupational Health, School of Population and Global Health, McGill University, Montreal, Quebec, Canada.; Department of Medicine, McGill University Health Centre, Montreal, Quebec, Canada., Saeed YA; Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Ontario, Canada., Kolla G; Canadian Centre for Substance Use Research, University of Victoria, Victoria, British Columbia, Canada., Kunden RD; Department of Biochemistry, Microbiology, and Immunology, University of Saskatchewan, Saskatoon, Saskatchewan, Canada., Okwor CIA; Department of Biochemistry, Microbiology, and Immunology, University of Ottawa, Ottawa, Ontario, Canada., Wallace HL; Division of Biomedical Sciences, Faculty of Medicine, Memorial University of Newfoundland, St. John's, Newfoundland and Labrador, Canada., Mendlowitz A; Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada.; Toronto Health Economics and Technology Assessment (THETA) Collaborative, University Health Network, Toronto, Ontario, Canada., Liu CH; Department of Microbiology and Immunology, Dalhousie University, Halifax, Nova Scotia, Canada.; Graduate Institute of Medical Sciences, College of Medicine, Taipei Medical University, Taipei, Taiwan., Mazouz S; Département de Microbiologie, Infectiologie et Immunologie, Université de Montréal, Montreal, Quebec, Canada., D'souza S; Department of Microbiology, Immunology, and Infectious Diseases, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada., Perciani CT; Soham and Shaila Ajmera Family Transplant Centre, Toronto General Hospital Research Institute, Toronto, Ontario, Canada., Rheault M; Department of Microbiology and Immunology, McGill University, Montreal, Quebec, Canada., Palmer MA; Department of Biochemistry, Microbiology, and Immunology, University of Saskatchewan, Saskatoon, Saskatchewan, Canada., Palayew A; Department of Epidemiology, University of Washington, Seattle, Washington, USA., Abdelnabi MN; Centre de Recherche du Centre Hospitalier de l'Université de Montréal, Montreal, Quebec, Canada., Cunningham EB; Kirby Institute, University of New South Wales Sydney, Sydney, New South Wales, Australia. |
| Πηγή: | Canadian liver journal [Can Liver J] 2021 Feb 24; Vol. 4 (1), pp. 4-7. Date of Electronic Publication: 2021 Feb 24 (Print Publication: 2021). |
| Τύπος έκδοσης: | Journal Article |
| Γλώσσα: | English |
| Στοιχεία περιοδικού: | Publisher: University of Toronto Press Country of Publication: Canada NLM ID: 101778326 Publication Model: eCollection Cited Medium: Internet ISSN: 2561-4444 (Electronic) Linking ISSN: 25614444 NLM ISO Abbreviation: Can Liver J Subsets: PubMed not MEDLINE |
| Imprint Name(s): | Original Publication: Toronto, ON Canada : University of Toronto Press, [2018]- |
| Competing Interests: | The authors have no conflict of interest to disclose. |
| References: | AIDS Behav. 2021 Feb;25(2):354-359. (PMID: 32705370) Int J Drug Policy. 2020 Sep;83:102821. (PMID: 32591222) Drug Alcohol Depend. 2020 Sep 1;214:108176. (PMID: 32717504) Liver Int. 2020 Mar;40(3):522-529. (PMID: 31815353) BMJ. 2020 Jun 9;369:m2294. (PMID: 32518177) AIDS Behav. 2020 Sep;24(9):2466-2468. (PMID: 32333209) Int J Drug Policy. 2020 Sep;83:102880. (PMID: 32739148) Hepatology. 2020 Aug;72(2):723-728. (PMID: 32275784) Int J Drug Policy. 2020 Sep;83:102832. (PMID: 32654930) JAMA Netw Open. 2020 May 1;3(5):e204192. (PMID: 32374397) Int J Drug Policy. 2020 Sep;83:102851. (PMID: 32736959) Int J Drug Policy. 2020 Sep;83:102895. (PMID: 32741718) BMC Infect Dis. 2018 Jun 19;18(1):281. (PMID: 29914381) J Hepatol. 2021 Jan;74(1):31-36. (PMID: 32777322) J Int AIDS Soc. 2020 Jul;23(7):e25583. (PMID: 32697423) |
| Contributed Indexing: | Keywords: COVID-19; SARS-CoV-2; hepatitis C elimination; people who use drugs Author Affiliation; priority populations |
| Entry Date(s): | Date Created: 20220822 Latest Revision: 20220823 |
| Update Code: | 20260130 |
| PubMed Central ID: | PMC9203169 |
| DOI: | 10.3138/canlivj-2020-0027 |
| PMID: | 35991473 |
| Βάση Δεδομένων: | MEDLINE |
καταχωρήστε σχόλιο πρώτοι!